InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,601.20
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.24
(
0.13%
)
Bitcoin
63,150.00
(
-1.33%
)
Post# of 642319
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TraderUsa

Send PM Follow Ignore
Followers 79
Posts 7846
Boards Moderated 2
Alias Born 05/05/2011

TraderUsa

Re: None

Thursday, 02/04/2021 4:50:16 PM

Thursday, February 04, 2021 4:50:16 PM

Post# of 642319
Good session for SLRX. This stock has a low float with only 19MM shares.

This biotech has two phase I cancer treatments based on the protein inhibitor LSD1. This system is the most innovative and promising thing currently available against cancer. Salarius pharma is one of the few companies in the market that has studies with these inhibitors. The long-term target price is above $10.

An important factor is that the former investors of Flex pharma (made a merger with Salarius Pharma) have warrants in place with a conversion price at $15. This means that all parties will do their best to reach that price.

It is possibly one of the market opportunities with the most potential in the medium term.

Best regards and good luck.

Is my humble opinion.

Do not forget to go through this ihub :
http://investorshub.advfn.com/boards/board.aspx?board_id=20991

Gainers Nasdaq Stocks Traders

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up